The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor

Molecular and Cellular Biology

Volumn 32, Issue 16, 2012, Pages 3190-3202

  Wang, Hongbo ^a   Jiang, Ming ^b   Cui, Hongmei ^a   Chen, Mengqian ^c   Buttyan, Ralph ^d   Hayward, Simon W ^b   Hai, Tsonwin ^e   Wang, Zhengxin ^f   Yan, Chunhong ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c University of South Carolina   (United States)

^d VANCOUVER PROSTATE CENTRE   (Canada)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ANDROGEN; ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL NUCLEUS; CELL PROLIFERATION; CELL STRESS; GENE EXPRESSION; GENE TRANSLOCATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIUM; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84865129257     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00159-12     Document Type: Article

References (67)

1. Adachi M, et al. 2000. Androgen-insensitivity syndrome as a possible coactivator disease. N. Engl. J. Med. 343:856-862.
2. Andersen R, et al. 2010. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17:535-546.
3. Beleza-Meireles A, et al. 2008. Activating transcription 3: a hormone responsive gene in the etiology of hypospadias. Eur. J. Endocrinol. 158: 729-739.
4. Best CJM, et al. 2005. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin. Cancer Res. 11:6823-6834.
5. Brinkmann AO. 2001. Molecular basis of androgen insensitivity. Mol. Cell Endocrinol. 179:105-109.
6. Cai C, et al. 2011. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20:457-471.
7. Carson-Jurica MA, Schrader WT, O'Malley BW. 1990. Steroid receptor family: structure and functions. Endocr. Rev. 11:201-220.
8. Centenera MM, Harris JM, Tilley WD, Butler LM. 2008. The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol. Endocrinol. 22:2373-2382.
9. Chen BPC, Liang G, Whelan J, Hai T. 1994. ATF3 and ATF3ΔZip: transcriptional repression versus activation by alternatively spliced isoforms. J. Biol. Chem. 269:15819-15826.
10. Chen SY, et al. 2006. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer proliferation. Oncogene 25: 7212-7223.
11. Gao N, et al. 2003. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcripitonal regulation of prostatic genes. Mol. Endocrinol. 17:1484-1507.
12. Gilchrist M, et al. 2006. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 441:173-178.
13. Hai T, Hartman MG. 2001. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 273:1-11.
14. Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U. 1999. ATF3 and stress responses. Gene Expr. 7:321-325.
15. Hai T, Wolford CC, Chang Y-S. 2010. ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? Gene Exp. 15:1-11.
16. Hartman MG, et al. 2004. Role for activating transcription factor 3 in stress-induced β-cell apoptosis. Mol. Cell. Biol. 24:5721-5732.
17. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM. 1999. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH2-terminal domain. J. Biol. Chem. 274:37219-37225.
18. He B, Kemppainen JA, Wilson EM. 2000. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 275:22986-22994.
19. He B, Lee LW, Minges JT, Wilson EM. 2002. Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J. Biol. Chem. 277:25631-25639.
20. Heemers HV, Tindall DJ. 2005. Androgen receptor coregulatory proteins as potential therapeutic targets in the treatments of prostate cancer. Curr. Cancer Ther. Rev. 1:175-186.
21. Heemers HW, Tindall DJ. 2008. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28:778-808.
22. Jiang H-Y, et al. 2004. Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol. Cell. Biol. 24: 1365-1377.
23. Jorgensen JS, Nilson JH. 2001. AR suppresses transcription of the α glycoprotein hormone subunit gene through protein-protein interactions with cJun and activating transcription factor 2. Mol. Endocrinol. 15: 1496-1504.
24. Kalfa N, Philibert P, Sultan C. 2008. Is hypospadias a genetic, endocrine or environmental disease, or still an unexplained malformation? Int. J. Androl. 32:187-197.
25. Kang Y, Chen C, Massague J. 2003. A self-enabling TGFß response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial Cells. Mol. Cell 11:915-926.
26. Ketola K, Vainio P, Fey V, Kallioniemi O, Iljin K. 2010. Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. Mol. Cancer Ther. 9:3175-3185.
27. Kourtis N, Tavernarakis N. 2011. Cellular stress response pathways and ageing: intricate molecular relationships. EMBO J. 30:2520-2531.
28. Lamont KR, Tindall DJ. 2010. Androgen regulation of gene expression. Adv. Cancer Res. 107:137-162.
29. Landschulz WH, Johnson PF, McKnight SL. 1988. The leucine zipper: A hypothetical structure common to a new class of DNA binding proteins. Science 240:1759-1764.
30. Langley E, Kemppainen JA, Wilson EM. 1998. Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J. Biol. Chem. 273: 92-101.
31. Lapointe J, et al. 2004. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 101: 811-816.
32. Li J, Fu J, Toumazou C, Yoon H-G, Wong J. 2006. A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol. Endocrinol. 20:776-785.
33. Liao G, et al. 2003. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J. Biol. Chem. 278:5052-5061.
34. Lin C, et al. 2009. Nuclear receptor-induced chromosomal proximity and DNA breaks underlies specific translocations in cancer. Cell 139:1069-1083.
35. Lin D-Y, et al. 2004. Negative regulation of androgen receptor transcriptional activity by Daxx. Mol. Cell. Biol. 24:10529-10541.
36. Liu G-Z, Wang H, Wang Z. 2003. Identification of a highly conserved domain in the androgen receptor that suppresses the DNA-binding domain-DNA interactions. J. Biol. Chem. 278:14956-14960.
37. Liu W, et al. 2011. KAI1 gene is engaged in NDRG1 gene-mediated metastasis suppression through the ATF3-NFκB complex in human prostate cancer. J. Biol. Chem. 286:18949-18959.
38. Mani R-S, et al. 2009. Induced chromosomal proximity and gene fusions in prostate cancer. Science 326:1230.
39. Mantoni TS, Reid G, Garrett MD. 2006. Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner. Oncogene 25:3139-3149.
40. Massie CE, et al. 2007. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep. 8:871-878.
41. Mo P, Wang H, Lu H, Boyd DD, Yan C. 2010. MDM2 mediates ubiquitination and degradation of activating transcription factor 3. J. Biol. Chem. 285:26908-26915.
42. Ni L, Yang C-S, Gioeli D, Frierson H, Toft DO, Paschal BM. 2010. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol. Cell. Biol. 30:1243-1253.
43. Norris J, et al. 2009. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol. Cell 36:405-416.
44. Pan Y, Chen H, Siu F, Kilberg MS. 2003. Amino acid deprivation and endoplasmic reticulum stress induce expression of multiple activating transcription factor-3 mRNA species that, when overexpressed in HepG2 cells, modulate transcription by the human asparagine synthetase promoter. J. Biol. Chem. 278:38402-38412.
45. Pelzer AE, et al. 2006. The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J. Urol. 175:1517-1522.
46. Phizicky E, Fields S. 1995. Protein-protein interactions: Methods for detection and analysis. Microbiol. Rev. 59:94-123.
47. Qi W, Wu H, Yang L, Boyd DD, Wang Z. 2007. A novel function of caspase-8 in the regulation of androgen-receptor-driven gene expression. EMBO J. 26:65-75.
48. Quigley CA, et al. 1995. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev. 16:271-321.
49. Sato N, et al. 1997. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J. Biol. Chem. 272:17485-17494.
50. Scher HI, Sawyers CL. 2005. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23:8253-8261.
51. Shen M, Abate-Shen C. 2010. Molecular genetics of prostate cancer: new prospects for old challenges. Gene Dev. 24:1967-2000.
52. Shenk J, et al. 2001. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J. Biol. Chem. 276:38472-38479.
53. Stanbrough M, Leav I, Kwan PL, Bubley GJ, Balk SP. 2001. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl. Acad. Sci. U. S. A. 98:10823-10828.
54. Tam NN, Gao Y, Leung YK, Ho SM. 2003. Androgenic regulation of oxidative stress in the rat prostate: Involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am. J. Pathol. 163:2513-2522.
55. Taylor B, et al. 2010. Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11-22.
56. Tomlins SA, et al. 2007. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39:41-51.
57. Vander Griend DJ, et al. 2009. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Mol. Cancer Ther. 8:1340-1349.
58. Wang C, et al. 2003. Identification of a novel transcription factor, GAG ATA-binding protein, involved in androgen-mediated expression of prostate-specific antigen. J. Biol. Chem. 278:32423-32430.
59. Wang H, Mo P, Ren S, Yan C. 2010. Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. J. Biol. Chem. 285:13201-13210.
60. Wang L, Hsu C-L, Chang C. 2005. Androgen receptor corepressors: an overview. Prostate 63:117-130.
61. Wang Q, et al. 2009. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245-256.
62. Weatherman RV, Fletterick RJ, Scanlan TS. 1999. Nuclear-receptor ligands and ligand-binding domains. Annu. Rev. Biochem. 68:559-581.
63. Yan C, Boyd DD. 2006. Histone H3 acetylation and H3 K4 methylation define distinct chromatin regions permissive for transgene expression. Mol. Cell. Biol. 26:6357-6371.
64. Yan C, Lu D, Hai T, Boyd DD. 2005. Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. EMBO J. 24: 2425-2435.
65. Yan C, Wang H, Boyd DD. 2001. KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-κB binding to the promoter as a consequence of IκBα-induced block of p65/p50 nuclear translocation. J. Biol. Chem. 276:1164-1172.
66. Yin X, Dewille JW, Hai T. 2008. A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene 27:2118-2127.
67. Zhang J, Thomas TZ, Kasper S, Matusik RJ. 2000. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141:4698-4710.